3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Apomorphine.
Acebutolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol.
Acepromazine
Acepromazine may decrease the vasoconstricting activities of Apomorphine.
Advertisement
Aldesleukin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Aldesleukin.
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Apomorphine.
Aliskiren
The risk or severity of adverse effects can be increased when Apomorphine is combined with Aliskiren.
Advertisement
Alosetron
Alosetron may increase the hypotensive activities of Apomorphine.
Alprenolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Apomorphine.
Advertisement
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Apomorphine.
Amiloride
The risk or severity of adverse effects can be increased when Apomorphine is combined with Amiloride.
Amineptin
Amineptine may decrease the antihypertensive activities of Apomorphine.
Amiodarone
Apomorphine may increase the QTc-prolonging activities of Amiodarone.
Amisulpride
The therapeutic efficacy of Amisulpride can be decreased when used in combination with Apomorphine.
Amitriptyline
Amitriptyline may decrease the antihypertensive activities of Apomorphine.
Amlodipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Amlodipine.
Amobarbital
Amobarbital may increase the hypotensive activities of Apomorphine.
Amoxapine
Amoxapine may decrease the antihypertensive activities of Apomorphine.
Amphetamine
The metabolism of Apomorphine can be decreased when combined with Amphetamine.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Apomorphine is combined with Amyl Nitrite.
Anagrelide
Apomorphine may increase the QTc-prolonging activities of Anagrelide.
Apraclonidine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Apraclonidine.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Apomorphine.
Arsenic Trioxide
Apomorphine may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Apomorphine may increase the QTc-prolonging activities of Artemether.
Asenapine
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Asenapine.
Atenolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Atenolol.
Azilsartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Azilsartan medoxomil.
Azithromycin
Apomorphine may increase the QTc-prolonging activities of Azithromycin.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Apomorphine.
Barbital
Barbital may increase the hypotensive activities of Apomorphine.
Bedaquiline
Apomorphine may increase the QTc-prolonging activities of Bedaquiline.
Benazepril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bendroflumethiazide.
Benzylpenicilloyl polylysine
Apomorphine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
Bepridil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bepridil.
Betaxolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
Bisoprolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
Bopindolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
Bortezomib
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bortezomib.
Bretylium
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bretylium.
Brexpiprazole
Brexpiprazole may decrease the vasoconstricting activities of Apomorphine.
Brimonidine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Brimonidine.
Bromocriptine
Bromocriptine may increase the vasoconstricting activities of Apomorphine.
Bumetanide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bumetanide.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Apomorphine.
Bupivacaine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bupivacaine.
Bupranolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
Bupropion
The risk or severity of adverse effects can be increased when Apomorphine is combined with Bupropion.
Butriptyline
Butriptyline may decrease the antihypertensive activities of Apomorphine.
Cabergoline
Cabergoline may increase the vasoconstricting activities of Apomorphine.
Canagliflozin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Candesartan cilexetil.
Captopril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Captopril.
Cariprazine
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Cariprazine.
Carteolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Carvedilol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Carvedilol.
Celiprolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Celiprolol.
Ceritinib
Apomorphine may increase the QTc-prolonging activities of Ceritinib.
Chloroquine
Apomorphine may increase the QTc-prolonging activities of Chloroquine.
Chlorothiazide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorothiazide.
Chlorpromazine
The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Apomorphine.
Chlorprothixene
The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Apomorphine.
Chlorthalidone
The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorthalidone.
Cilazapril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Cilazapril.
Ciprofloxacin
Apomorphine may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Apomorphine may increase the QTc-prolonging activities of Cisapride.
Citalopram
Apomorphine may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Apomorphine may increase the QTc-prolonging activities of Clarithromycin.
Clevidipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Clofarabine.
Clomipramine
Clomipramine may decrease the antihypertensive activities of Apomorphine.
Clonidine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Clonidine.
Clozapine
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Clozapine.
Conivaptan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Conivaptan.
Crizotinib
Apomorphine may increase the QTc-prolonging activities of Crizotinib.
Dapagliflozin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.
Dapiprazole
Dapiprazole may decrease the vasoconstricting activities of Apomorphine.
Desflurane
The risk or severity of adverse effects can be increased when Apomorphine is combined with Desflurane.
Desipramine
Desipramine may decrease the antihypertensive activities of Apomorphine.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Apomorphine.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dexmedetomidine.
Dextroamphetamine
Dextroamphetamine may decrease the vasoconstricting activities of Apomorphine.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Diclofenamide.
Dihydroergotamine
Dihydroergotamine may increase the vasoconstricting activities of Apomorphine.
Diltiazem
The risk or severity of adverse effects can be increased when Apomorphine is combined with Diltiazem.
Dinutuximab
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dipyridamole.
Disopyramide
Apomorphine may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Apomorphine may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Dolasetron may increase the hypotensive activities of Apomorphine.
Domperidone
Apomorphine may increase the QTc-prolonging activities of Domperidone.
Dothiepin
Dosulepin may decrease the antihypertensive activities of Apomorphine.
Doxazosin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Doxazosin.
Doxepin
Doxepin may decrease the antihypertensive activities of Apomorphine.
Dronedarone
Apomorphine may increase the QTc-prolonging activities of Dronedarone.
Droperidol
The therapeutic efficacy of Droperidol can be decreased when used in combination with Apomorphine.
Droxidopa
Apomorphine may increase the hypertensive activities of Droxidopa.
Duloxetine
Apomorphine may increase the orthostatic hypotensive activities of Duloxetine.
Eliglustat
Apomorphine may increase the QTc-prolonging activities of Eliglustat.
Empagliflozin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.
Enalapril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat.
Epinephrine
Epinephrine may decrease the vasoconstricting activities of Apomorphine.
Eplerenone
The risk or severity of adverse effects can be increased when Apomorphine is combined with Eplerenone.
Epoprostenol
The risk or severity of adverse effects can be increased when Apomorphine is combined with Epoprostenol.
Eprosartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Eprosartan.
ergoloid mesylates, USP
Ergoloid mesylate may increase the vasoconstricting activities of Apomorphine.
Ergonovine
Ergonovine may increase the vasoconstricting activities of Apomorphine.
Ergotamine
Ergotamine may increase the vasoconstricting activities of Apomorphine.
Erythromycin
Apomorphine may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Apomorphine may increase the QTc-prolonging activities of Escitalopram.
Esmolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Esmolol.
Ethacrynate
The risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.
Felodipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Felodipine.
Fenoldopam
The risk or severity of adverse effects can be increased when Apomorphine is combined with Fenoldopam.
Flecainide
Apomorphine may increase the QTc-prolonging activities of Flecainide.
Fluoxetine
Apomorphine may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
The therapeutic efficacy of Flupentixol can be decreased when used in combination with Apomorphine.
Fluphenazine
The therapeutic efficacy of Fluphenazine can be decreased when used in combination with Apomorphine.
Fosinopril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Fosinopril.
Furazolidone
The metabolism of Apomorphine can be decreased when combined with Furazolidone.
Furosemide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Furosemide.
Gadobenate
Apomorphine may increase the QTc-prolonging activities of Gadobenic acid.
Gemifloxacin
Apomorphine may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Apomorphine may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Apomorphine may increase the QTc-prolonging activities of Goserelin.
Granisetron
Granisetron may increase the hypotensive activities of Apomorphine.
Guanfacine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Guanfacine.
Haloperidol
The therapeutic efficacy of Haloperidol can be decreased when used in combination with Apomorphine.
Halothane
The risk or severity of adverse effects can be increased when Apomorphine is combined with Halothane.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Apomorphine.
Hyaluronidase
Hyaluronidase may increase the vasoconstricting activities of Apomorphine.
Hyaluronidase, Ovine
Hyaluronidase may increase the vasoconstricting activities of Apomorphine.
Hydralazine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydrochlorothiazide.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydroflumethiazide.
Ibutilide
Apomorphine may increase the QTc-prolonging activities of Ibutilide.
Iloperidone
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Iloperidone.
Iloprost
The risk or severity of adverse effects can be increased when Apomorphine is combined with Iloprost.
Imidapril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Imidapril.
Imipramine
Imipramine may decrease the antihypertensive activities of Apomorphine.
Indapamide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Indapamide.
Indoramin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Indoramin.
Iproniazid
The metabolism of Apomorphine can be decreased when combined with Iproniazid.
Irbesartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Irbesartan.
Isocarboxazid
The metabolism of Apomorphine can be decreased when combined with Isocarboxazid.
Isoflurane
The risk or severity of adverse effects can be increased when Apomorphine is combined with Isoflurane.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Apomorphine is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Apomorphine is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Isoxsuprine.
Isradipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Isradipine.
Labetalol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Lacidipine
Apomorphine may increase the hypotensive activities of Lacidipine.
Lenvatinib
Apomorphine may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Apomorphine may increase the QTc-prolonging activities of Lenvatinib.
Lercanidipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Lercanidipine.
Leuprolide
Apomorphine may increase the QTc-prolonging activities of Leuprolide.
Levobetaxolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.
Levobunolol
The risk or severity of adverse effects can be increased when Apomorphine is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Levobupivacaine.
Levodopa
Apomorphine may increase the orthostatic hypotensive activities of Levodopa.
Levofloxacin
Apomorphine may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Apomorphine may increase the QTc-prolonging activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Apomorphine.
Levosimendan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Levosimendan.
Lisdexamfetamine
Lisdexamfetamine may decrease the vasoconstricting activities of Apomorphine.
Lisdexamfetamine Dimesylate
Lisdexamfetamine may decrease the vasoconstricting activities of Apomorphine.
Lisinopril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril.
Lofexidine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Lofexidine.
Lopinavir
Apomorphine may increase the QTc-prolonging activities of Lopinavir.
Losartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Losartan.
Loxapine
The therapeutic efficacy of Loxapine can be decreased when used in combination with Apomorphine.
Lumefantrine
Apomorphine may increase the QTc-prolonging activities of Lumefantrine.
Lurasidone
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.
Mannitol
The risk or severity of adverse effects can be increased when Apomorphine is combined with Mannitol.
Mecamylamine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Mecamylamine.
MELITRACEN
Melitracen may decrease the antihypertensive activities of Apomorphine.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Apomorphine.
Mepindolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Mepindolol.
Mepirodipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Barnidipine.
Mesoridazine
The therapeutic efficacy of Mesoridazine can be decreased when used in combination with Apomorphine.
Methadone
Apomorphine may increase the QTc-prolonging activities of Methadone.
Methazolamide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Methazolamide.
Methohexital
Methohexital may increase the hypotensive activities of Apomorphine.
Methotrimeprazine
The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Apomorphine.
Methyclothiazide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyclothiazide.
Methyldopa
The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyldopa.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyldopa.
Methylene blue
The metabolism of Apomorphine can be decreased when combined with Methylene blue.
Methylergonovine
Methylergometrine may increase the vasoconstricting activities of Apomorphine.
Methylphenidate
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.
Metipranolol
The risk or severity of adverse effects can be increased when Apomorphine is combined with Metipranolol.
Metoclopramide
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Metoclopramide.
Metolazone
The risk or severity of adverse effects can be increased when Apomorphine is combined with Metolazone.
Metoprolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Metoprolol.
Metylperon
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Melperone.
Mianserin
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Mianserin.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Apomorphine.
Milnacipran
Milnacipran may increase the tachycardic activities of Apomorphine.
Minaprine
The metabolism of Apomorphine can be decreased when combined with Minaprine.
Minoxidil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Minoxidil.
Mirtazapine
Mirtazapine may decrease the antihypertensive activities of Apomorphine.
Moclobemide
The metabolism of Apomorphine can be decreased when combined with Moclobemide.
Moexipril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Moexipril.
Molindone
The therapeutic efficacy of Molindone can be decreased when used in combination with Apomorphine.
Morphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Morphine.
Moxifloxacin
Apomorphine may increase the QTc-prolonging activities of Moxifloxacin.
Moxonidine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Moxonidine.
Nabilone
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nabilone.
Nadolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Nadolol.
Nebivolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Nebivolol.
Nefazodone
Nefazodone may decrease the vasoconstricting activities of Apomorphine.
Nesiritide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nesiritide.
Nialamide
The metabolism of Apomorphine can be decreased when combined with Nialamide.
Nicardipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nicardipine.
Nicergoline
Nicergoline may decrease the vasoconstricting activities of Apomorphine.
Nicorandil
Nicorandil may increase the hypotensive activities of Apomorphine.
Nifedipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nifedipine.
Nilotinib
Apomorphine may increase the QTc-prolonging activities of Nilotinib.
Nilvadipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nilvadipine.
Nimodipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nimodipine.
Nisoldipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nisoldipine.
Nitrendipine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitric Oxide.
Nitroglycerin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitroglycerin.
Nitroprusside
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitroprusside.
Nortriptyline
Nortriptyline may decrease the antihypertensive activities of Apomorphine.
Obinutuzumab
The risk or severity of adverse effects can be increased when Apomorphine is combined with Obinutuzumab.
Ofloxacin
Apomorphine may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine.
Olmesartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Olmesartan.
Ondansetron
Ondansetron may increase the hypotensive activities of Apomorphine.
Opipramol
Opipramol may decrease the antihypertensive activities of Apomorphine.
Oxprenolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
Paclitaxel
The risk or severity of adverse effects can be increased when Apomorphine is combined with Paclitaxel.
Paliperidone
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Paliperidone.
Palonosetron
Palonosetron may increase the hypotensive activities of Apomorphine.
Panobinostat
Apomorphine may increase the QTc-prolonging activities of Panobinostat.
Papaverine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Papaverine.
Paregoric
The risk or severity of adverse effects can be increased when Apomorphine is combined with Morphine.
Pargyline
The metabolism of Apomorphine can be decreased when combined with Pargyline.
Pazopanib
Apomorphine may increase the QTc-prolonging activities of Pazopanib.
Penbutolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Penbutolol.
Pentamidine
Apomorphine may increase the QTc-prolonging activities of Pentamidine.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Apomorphine.
Perflutren
Apomorphine may increase the QTc-prolonging activities of Perflutren.
Periciazine
The therapeutic efficacy of Propericiazine can be decreased when used in combination with Apomorphine.
Perindopril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Perindopril.
Perphenazine
The therapeutic efficacy of Perphenazine can be decreased when used in combination with Apomorphine.
Phenelzine
The metabolism of Apomorphine can be decreased when combined with Phenelzine.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Apomorphine.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoxybenzamine.
Phentolamine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Phentolamine.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Apomorphine is combined with Phentolamine.
Pimavanserin
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Pimavanserin.
Pimozide
The therapeutic efficacy of Pimozide can be decreased when used in combination with Apomorphine.
Pindolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Apomorphine is combined with Pipamperone.
Pizotyline
Pizotifen may decrease the vasoconstricting activities of Apomorphine.
Practolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Practolol.
Pramipexole
The risk or severity of adverse effects can be increased when Apomorphine is combined with Pramipexole.
Prazosin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Prazosin.
Primaquine
Apomorphine may increase the QTc-prolonging activities of Primaquine.
Primidone
Primidone may increase the hypotensive activities of Apomorphine.
Procainamide
Apomorphine may increase the QTc-prolonging activities of Procainamide.
Procaine
The metabolism of Apomorphine can be decreased when combined with Procaine.
Procarbazine
The metabolism of Apomorphine can be decreased when combined with Procarbazine.
Prochlorperazine
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Apomorphine.
Promazine
The therapeutic efficacy of Promazine can be decreased when used in combination with Apomorphine.
Propafenone
Apomorphine may increase the atrioventricular blocking (AV block) activities of Propafenone.
Propiomazine
Propiomazine may decrease the vasoconstricting activities of Apomorphine.
Propiverine
Propiverine may decrease the vasoconstricting activities of Apomorphine.
Propofol
The risk or severity of adverse effects can be increased when Apomorphine is combined with Propofol.
Propranolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Propranolol.
Protriptyline
Protriptyline may decrease the antihypertensive activities of Apomorphine.
Quetiapine
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Quetiapine.
Quetiapine fumarate
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Quinapril.
Quinidine
Apomorphine may increase the QTc-prolonging activities of Quinidine.
Quinine
Apomorphine may increase the QTc-prolonging activities of Quinine.
Racepinephrine
Racepinephrine may decrease the vasoconstricting activities of Apomorphine.
Ramipril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Ramipril.
Rasagiline
The metabolism of Apomorphine can be decreased when combined with Rasagiline.
Remifentanil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Remifentanil.
Reserpine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Reserpine.
Riociguat
The risk or severity of adverse effects can be increased when Apomorphine is combined with Riociguat.
Risperidone
Apomorphine may increase the hypotensive activities of Risperidone.
Ropinirole
The risk or severity of adverse effects can be increased when Apomorphine is combined with Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Ropivacaine.
Rotigotine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Rotigotine.
Sacubitril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Sacubitril.
Saquinavir
Apomorphine may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Apomorphine may increase the QTc-prolonging activities of Saquinavir.
Secobarbital
Secobarbital may increase the hypotensive activities of Apomorphine.
Selegiline
The metabolism of Apomorphine can be decreased when combined with Selegiline.
Sertindole
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Sertindole.
Sevoflurane
The risk or severity of adverse effects can be increased when Apomorphine is combined with Sevoflurane.
Silodosin
Silodosin may decrease the vasoconstricting activities of Apomorphine.
Sotalol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Sotalol.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Apomorphine.
Streptokinase
The risk or severity of adverse effects can be increased when Apomorphine is combined with Streptokinase.
Sufentanil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil.
Sulfisoxazole
Apomorphine may increase the QTc-prolonging activities of Sulfisoxazole.
Talinolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Talinolol.
Tamsulosin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Tamsulosin.
Telavancin
Apomorphine may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Apomorphine may increase the QTc-prolonging activities of Telithromycin.
Telmisartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Telmisartan.
Terazosin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Terazosin.
Terbutaline
Apomorphine may increase the atrioventricular blocking (AV block) activities of Terbutaline.
Terbutaline Sulfate
Apomorphine may increase the atrioventricular blocking (AV block) activities of Terbutaline.
Tertatolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Tertatolol.
Tetrabenazine
Apomorphine may increase the QTc-prolonging activities of Tetrabenazine.
Thalidomide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Thalidomide.
Thiamylal
Thiamylal may increase the hypotensive activities of Apomorphine.
Thiopental
Thiopental may increase the hypotensive activities of Apomorphine.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Apomorphine.
Thioproperazine
The therapeutic efficacy of Thioproperazine can be decreased when used in combination with Apomorphine.
Thioridazine
The therapeutic efficacy of Thioridazine can be decreased when used in combination with Apomorphine.
Thiothixene
The therapeutic efficacy of Thiothixene can be decreased when used in combination with Apomorphine.
Tianeptine
Tianeptine may decrease the antihypertensive activities of Apomorphine.
Timolol
Apomorphine may increase the atrioventricular blocking (AV block) activities of Timolol.
Timolol Anhydrous
Apomorphine may increase the atrioventricular blocking (AV block) activities of Timolol.
Tizanidine
The serum concentration of Tizanidine can be increased when it is combined with Apomorphine.
Tolazoline
The risk or severity of adverse effects can be increased when Apomorphine is combined with Tolazoline.
Tolcapone
The risk or severity of adverse effects can be increased when Apomorphine is combined with Tolcapone.
Toloxatone
The metabolism of Apomorphine can be decreased when combined with Toloxatone.
Toremifene
Apomorphine may increase the QTc-prolonging activities of Toremifene.
Torsemide
The risk or severity of adverse effects can be increased when Apomorphine is combined with Torasemide.
Trandolapril
The risk or severity of adverse effects can be increased when Apomorphine is combined with Trandolapril.
Tranylcypromine
The metabolism of Apomorphine can be decreased when combined with Tranylcypromine.
Trazodone
Trazodone may decrease the vasoconstricting activities of Apomorphine.
Tretinoin
The risk or severity of adverse effects can be increased when Apomorphine is combined with Tretinoin.
Triamterene
The risk or severity of adverse effects can be increased when Apomorphine is combined with Triamterene.
Trifluoperazine
The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Apomorphine.
Trimipramine
Trimipramine may decrease the antihypertensive activities of Apomorphine.
Tropisetron
Tropisetron may increase the hypotensive activities of Apomorphine.
Urapidil
Urapidil may decrease the vasoconstricting activities of Apomorphine.
Valsartan
The risk or severity of adverse effects can be increased when Apomorphine is combined with Valsartan.
Vandetanib
Apomorphine may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
Apomorphine may increase the QTc-prolonging activities of Vemurafenib.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Apomorphine.
Verapamil
The risk or severity of adverse effects can be increased when Apomorphine is combined with Verapamil.
Vortioxetine
Vortioxetine may increase the hypotensive activities of Apomorphine.
Ziprasidone
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Ziprasidone.
Zotepine
The therapeutic efficacy of Apomorphine can be decreased when used in combination with Zotepine.
Zuclopenthixol
The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Apomorphine.
